Board Change • May 20
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. No independent directors (7 non-independent directors). Director Mikael Kubista was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Apr 02
Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO). Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares.
The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026.
The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin.
Devyser AB completed the acquisition of CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) on April 1, 2026. The acquisition was conditional upon the receipt of all necessary clearances, approvals, decisions and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act. This closing condition has been fulfilled on April 1, 2026. The acquisition is consolidated from and including April 1, 2026 and is expected to have a positive impact on Devyser’s gross profit as well as EBIT. 공시 • Feb 12
Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million. Devyser AB agreed to acquire CyberGene AB from Level Bio AB (publ) (NGM:LEVBIO) for SEK 12.2 million on February 11, 2026. The consideration consists of common equity of Devyser AB having a value of SEK 12.2 million to be issued for common equity of CyberGene AB. As part of consideration, SEK 12.2 million is paid towards common equity of CyberGene AB.
The transaction is subject to approval by regulatory board / committee. The expected completion of the transaction is April 1, 2026.
The acquisition strengthens Devyser’s customer offering within the aneuploidy segment and is expected to have a positive impact on Devyser’s gross profit and gross margin. The acquisition is fully financed through a directed issue of new shares in Devyser to the seller, to be paid by way of set-off against the seller’s claim on payment of the purchase price. Based on the authorization granted by the Annual General Meeting on 14 May 2025, the Board of Directors intends, subject to receipt of the necessary clearance from the Inspectorate of Strategic Products, to resolve upon an issue of new shares in Devyser. Level Bio AB (publ), as the seller of Cybergene, will be entitled to subscribe for the new shares. Reported Earnings • Apr 26
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr5.67m (down 33% from 1Q 2023). Net loss: kr2.46m (loss widened 343% from 1Q 2023). 공시 • Mar 27
AlphaHelix Molecular Diagnostics AB (publ) to Report Q1, 2024 Results on Apr 25, 2024 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024 공시 • Mar 20
AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024 AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Apr 18, 2024. Reported Earnings • Feb 25
Full year 2023 earnings released: kr0.15 loss per share (vs kr0.035 loss in FY 2022) Full year 2023 results: kr0.15 loss per share (further deteriorated from kr0.035 loss in FY 2022). Revenue: kr26.6m (down 23% from FY 2022). Net loss: kr9.48m (loss widened 326% from FY 2022). 공시 • Jan 24
AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr6.54m (up 19% from 3Q 2022). Net loss: kr2.30m (loss widened 93% from 3Q 2022). 공시 • Sep 27
AlphaHelix Molecular Diagnostics AB (publ) to Report Q3, 2023 Results on Oct 26, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 28
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr5.39m (down 6.3% from 2Q 2022). Net loss: kr2.36m (loss narrowed 2.4% from 2Q 2022). 공시 • Jul 26
AlphaHelix Molecular Diagnostics AB (publ) to Report Q2, 2023 Results on Aug 24, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report Q2, 2023 results on Aug 24, 2023 공시 • May 31
AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023 AlphaHelix Molecular Diagnostics AB (publ), Annual General Meeting, Jun 29, 2023. Reported Earnings • Apr 20
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr8.48m (down 35% from 1Q 2022). Net loss: kr554.0k (down 139% from profit in 1Q 2022). Buying Opportunity • Apr 03
Now 34% undervalued after recent price drop Over the last 90 days, the stock is down 31%. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Mar 07
Now 37% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be €0.058, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Feb 24
Full year 2022 earnings released: kr0.035 loss per share (vs kr0.087 profit in FY 2021) Full year 2022 results: kr0.035 loss per share (down from kr0.087 profit in FY 2021). Revenue: kr34.7m (down 21% from FY 2021). Net loss: kr2.22m (down 143% from profit in FY 2021). 공시 • Jan 18
AlphaHelix Molecular Diagnostics AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023 AlphaHelix Molecular Diagnostics AB (publ) announced that they will report fiscal year 2022 results on Feb 16, 2023 Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Joakim Grånemo was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr5.63m (down 16% from 3Q 2021). Net loss: kr1.19m (loss widened kr1.09m from 3Q 2021). Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: kr0.022 (vs kr0.031 in 1Q 2021) First quarter 2022 results: EPS: kr0.022 (down from kr0.031 in 1Q 2021). Revenue: kr13.1m (up 39% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Neven Zoric was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 22
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr13.2m (up 40% from 1Q 2021). Net income: kr1.42m (down 12% from 1Q 2021). Profit margin: 11% (down from 17% in 1Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr0.081 (up from kr0.029 in FY 2020). Revenue: kr44.7m (up 90% from FY 2020). Net income: kr5.16m (up 241% from FY 2020). Profit margin: 12% (up from 6.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Reported Earnings • Nov 01
Third quarter 2021 earnings released The company reported a mediocre third quarter result with weaker earnings and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr6.96m (up 42% from 3Q 2020). Net loss: kr107.0k (down 168% from profit in 3Q 2020). Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS kr0.056 (vs kr0.014 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr15.8m (up 153% from 2Q 2020). Net income: kr3.54m (up 363% from 2Q 2020). Profit margin: 22% (up from 12% in 2Q 2020). The increase in margin was driven by higher revenue.